BS_YE1MAQYJ
Spinal Cord Ependymoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Spinal Cord Ependymoma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- Spinal Cord Ependymoma
- overall_survival_months
- 64.48751642575559
- age_years
- 5.145
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HYPOXIA+0.285
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.273
- GLYCOLYSIS+0.268
- WNT_BETA_CATENIN_SIGNALING+0.265
- NOTCH_SIGNALING+0.253
- KRAS_SIGNALING_DN+0.225
- ESTROGEN_RESPONSE_LATE+0.221
- ANGIOGENESIS+0.193
- COAGULATION+0.181
- SPERMATOGENESIS+0.173
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.411
- PROTEIN_SECRETION-0.371
- INTERFERON_GAMMA_RESPONSE-0.355
- PI3K_AKT_MTOR_SIGNALING-0.327
- MYC_TARGETS_V2-0.314
- ANDROGEN_RESPONSE-0.297
- UNFOLDED_PROTEIN_RESPONSE-0.289
- MYC_TARGETS_V1-0.286
- ALLOGRAFT_REJECTION-0.263
- MITOTIC_SPINDLE-0.228
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_YE1MAQYJ | EPN | EPN Tumor | 0.837 |
| 2 | SJEPD031_R.RNA-Seq | EPN | Posterior Fossa EPN | 0.760 |
| 3 | BS_MKP2Y41Z | Posterior Fossa Ependymoma | — | 0.726 |
| 4 | BS_T4P3J13C | Posterior Fossa Ependymoma | — | 0.721 |
| 5 | MNG686 | — | — | 0.709 |
| 6 | TCGA-77-A5G8-01B-11R-A27Q-07 | — | cohortSQ2 | 0.708 |
| 7 | 0e8bcafe-b201-4c66-8a0b-d89a4fd7c7ae | — | — | 0.704 |
| 8 | MNG825 | — | — | 0.703 |
| 9 | C3N-02143 | — | cohortA1 | 0.688 |
| 10 | SRR1323174 | GTEX | — | 0.685 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HYPOXIA | 0.285 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.273 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.268 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.265 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.253 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.225 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.221 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.193 | Remibrutinib | — uncovered |
| COAGULATION | 0.181 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.173 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.169 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.153 | Inavolisib | — uncovered |
| MYOGENESIS | 0.128 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.111 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.068 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.051 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.047 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.047 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.046 | Inavolisib | — uncovered |